protein kinase AMP-activated non-catalytic subunit beta 2Genealiases: []
Q-omics provides the consensus-scored PRKAB2 profile across patient tissues and cancer cell-line models. PRKAB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRKAB2 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, PRKAB2 protein abundance shows 24,264 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where PRKAB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAB2 survival associations across molecular data types. PRKAB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAB2 RNA expression–survival associations across cancer types. High PRKAB2 expression shows unfavorable associations in MESO, KIRP, LUSC, THCA and HNSC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for PRKAB2 RNA expression.
This table summarizes PRKAB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKAB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAB2 shows lower tumor expression in THCA, UCEC and PRAD and higher tumor expression in HNSC, LIHC and LUSC. The HNSC box plot shows higher PRKAB2 RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with PRKAB2 in patient tissues and cancer cell lines. In patient samples, PRKAB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKAB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
